
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Novartis offers zoledronic acid injection (ZOMETA) for the treatmentof patients with documented bone metastases from solid tumors, includingprostate cancer, in conjunction with standard antineoplastic therapy.





